360 related articles for article (PubMed ID: 31165341)
1. Meta-analysis of IL-17 inhibitors in two populations of rheumatoid arthritis patients: biologic-naïve or tumor necrosis factor inhibitor inadequate responders.
Wu D; Hou SY; Zhao S; Hou LX; Jiao T; Xu NN; Zhang N
Clin Rheumatol; 2019 Oct; 38(10):2747-2756. PubMed ID: 31165341
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of secukinumab in active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis of phase III randomized controlled trials.
Huang Y; Fan Y; Liu Y; Xie W; Zhang Z
Clin Rheumatol; 2019 Oct; 38(10):2765-2776. PubMed ID: 31087226
[TBL] [Abstract][Full Text] [Related]
3. Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid Arthritis.
Wells AF; Curtis JR; Betts KA; Douglas K; Du EX; Ganguli A
Clin Ther; 2017 Aug; 39(8):1680-1694.e2. PubMed ID: 28734661
[TBL] [Abstract][Full Text] [Related]
4. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.
Genovese MC; Greenwald M; Cho CS; Berman A; Jin L; Cameron GS; Benichou O; Xie L; Braun D; Berclaz PY; Banerjee S
Arthritis Rheumatol; 2014 Jul; 66(7):1693-704. PubMed ID: 24623718
[TBL] [Abstract][Full Text] [Related]
5. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs.
Bergman GJ; Hochberg MC; Boers M; Wintfeld N; Kielhorn A; Jansen JP
Semin Arthritis Rheum; 2010 Jun; 39(6):425-41. PubMed ID: 20223500
[TBL] [Abstract][Full Text] [Related]
6. Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials.
Kunwar S; Dahal K; Sharma S
Rheumatol Int; 2016 Aug; 36(8):1065-75. PubMed ID: 27105880
[TBL] [Abstract][Full Text] [Related]
7. Placebo Response in Rheumatoid Arthritis Clinical Trials.
Bechman K; Yates M; Norton S; Cope AP; Galloway JB
J Rheumatol; 2020 Jan; 47(1):28-34. PubMed ID: 31043548
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis.
Gulácsi L; Zrubka Z; Brodszky V; Rencz F; Alten R; Szekanecz Z; Péntek M
Adv Ther; 2019 Mar; 36(3):721-745. PubMed ID: 30637590
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumor necrosis factor inhibitors: a systematic review and meta-analysis.
Abushouk AI; Ahmed H; Ismail A; Elmaraezy A; Badr AS; Gadelkarim M; Elnenny M
Rheumatol Int; 2017 Jul; 37(7):1053-1064. PubMed ID: 28236221
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
Sung YK; Lee YH
J Clin Pharm Ther; 2021 Aug; 46(4):984-992. PubMed ID: 33600008
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
12. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
[TBL] [Abstract][Full Text] [Related]
13. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.
Zintzaras E; Dahabreh IJ; Giannouli S; Voulgarelis M; Moutsopoulos HM
Clin Ther; 2008 Nov; 30(11):1939-55. PubMed ID: 19108784
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2.
McInnes IB; Chakravarty SD; Apaolaza I; Kafka S; Hsia EC; You Y; Kavanaugh A
RMD Open; 2019; 5(2):e000990. PubMed ID: 31565242
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis.
Wiens A; Venson R; Correr CJ; Otuki MF; Pontarolo R
Pharmacotherapy; 2010 Apr; 30(4):339-53. PubMed ID: 20334454
[TBL] [Abstract][Full Text] [Related]
17. Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis.
Siebert S; Coates LC; Schett G; Raychaudhuri SP; Chen W; Gao S; Seridi L; Chakravarty SD; Shawi M; Lavie F; Sharaf M; Zimmermann M; Kollmeier AP; Xu XL; Rahman P; Mease PJ; Deodhar A
Arthritis Rheumatol; 2024 Jun; 76(6):894-904. PubMed ID: 38253404
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and Safety of Iguratimod Monotherapy or Combined With Methotrexate in Treating Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Ouyang D; Ma YZ; Zou J; Wang YL; Chen Z; Yang YY; Zou B; Li X; Cao JZ
Front Pharmacol; 2022; 13():911810. PubMed ID: 35991879
[No Abstract] [Full Text] [Related]
19. Treatment of Dactylitis and Enthesitis in Psoriatic Arthritis with Biologic Agents: A Systematic Review and Metaanalysis.
Mourad A; Gniadecki R
J Rheumatol; 2020 Jan; 47(1):59-65. PubMed ID: 30824641
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of biologic agents in patients with active rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
Sung YK; Lee YH
Int J Clin Pharmacol Ther; 2022 Jan; 60(1):13-23. PubMed ID: 34622767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
